We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain TNDM Stock in Your Portfolio for Now
Read MoreHide Full Article
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) third-quarter growth is backed by its impressive range of new products. The robust international market expansion provides a favorable opportunity for the company’s growth. However, concerns loom over fierce competition and the adverse impact of macroeconomic challenges.
In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 36.2% compared with 16.1% growth of the industry and a 34% rise of the S&P 500 composite.
The renowned medical device company has a market capitalization of $1.99 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered a trailing four-quarter average earnings surprise of 8.28%.
Let’s delve deeper.
TNDM Stock’s Key Tailwinds
Focus on International Markets: Tandem Diabetes’ decision to expand globally aligns well with market demand and should help it take advantage of the significant market opportunities. The company’s sales in approximately 25 countries outside the United States accounted for 29.6% of its worldwide sales in the third quarter of 2024. Revenues outside the United States increased 31% year over year.
The company shipped approximately 11,000 pumps in 25 markets outside the United States. It began scaling Tandem Source outside the country, starting with Canada. The international markets in which it operates are typically less than 20% penetrated, indicating more growth potential.
Impressive Product Innovation Continues: Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people with diabetes. Its flagship t:slim X2 insulin pump software became compatible with Dexcom G7 and Dexcom G6 CGM systems in the third quarter of 2024. Following this development, t:slim X2 was approved for sale by Canada Health.
In September, t:slim X2 became compatible with Eli Lilly and Company’s Lyumjev. t:slim is also integrated with Abbott’s new FreeStyle Libre 2 Plus sensor. The breakthrough development has enabled t:slim X2 users in the United States to benefit from a hybrid closed-loop system that helps predict and prevent high and low blood sugar levels.
The latest addition to the pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy. The company’s extended wear infusion set technology Steadi-Set’s pivotal trial is on track to be completed by the end of 2024.
TNDM’s Sigi, ergonomic, rechargeable and detachable patch pumps are under development. Additionally, it is driving innovation in algorithms. The company is planning to roll out its newest algorithm on both h t:slim X2 and Mobi.
TNDM Stock’s Key Headwinds
Tough Competitive Pressure: Tandem Diabetes operates in a highly competitive environment dominated by firms ranging from large multinational corporations (with significant resources) to start-ups. The company’s primary competitors are major publicly traded medical device companies, divisions, or subsidiaries of publicly traded companies, including Insulet and Medtronic. In addition, several companies have been developing and marketing their insulin delivery systems and related software applications. These significant changes within the industry may affect the company’s business and operating results.
Image Source: Zacks Investment Research
Macroeconomic Headwinds Persist: The uncertainties related to the current global economic and political conditions would pose challenges for the company. Due to unfavorable general economic conditions, Tandem Diabetes’ profitability could decline and affect its overall financial performance. In the third quarter, the cost of sales increased 24.5% from the prior-year level.
Estimate Trend
The Zacks Consensus Estimate for 2024 loss per share has moved down 4.5% to $1.68 in the past 30 days.
The Zacks Consensus Estimate for 2024 revenues is pegged at $912.5 million, which suggests an increase of 22% from the year-ago reported number.
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.
Globus Medical, carrying a Zacks Rank #2 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.
Penumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Retain TNDM Stock in Your Portfolio for Now
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) third-quarter growth is backed by its impressive range of new products. The robust international market expansion provides a favorable opportunity for the company’s growth. However, concerns loom over fierce competition and the adverse impact of macroeconomic challenges.
In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 36.2% compared with 16.1% growth of the industry and a 34% rise of the S&P 500 composite.
The renowned medical device company has a market capitalization of $1.99 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered a trailing four-quarter average earnings surprise of 8.28%.
Let’s delve deeper.
TNDM Stock’s Key Tailwinds
Focus on International Markets: Tandem Diabetes’ decision to expand globally aligns well with market demand and should help it take advantage of the significant market opportunities. The company’s sales in approximately 25 countries outside the United States accounted for 29.6% of its worldwide sales in the third quarter of 2024. Revenues outside the United States increased 31% year over year.
The company shipped approximately 11,000 pumps in 25 markets outside the United States. It began scaling Tandem Source outside the country, starting with Canada. The international markets in which it operates are typically less than 20% penetrated, indicating more growth potential.
Impressive Product Innovation Continues: Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people with diabetes. Its flagship t:slim X2 insulin pump software became compatible with Dexcom G7 and Dexcom G6 CGM systems in the third quarter of 2024. Following this development, t:slim X2 was approved for sale by Canada Health.
In September, t:slim X2 became compatible with Eli Lilly and Company’s Lyumjev. t:slim is also integrated with Abbott’s new FreeStyle Libre 2 Plus sensor. The breakthrough development has enabled t:slim X2 users in the United States to benefit from a hybrid closed-loop system that helps predict and prevent high and low blood sugar levels.
The latest addition to the pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy. The company’s extended wear infusion set technology Steadi-Set’s pivotal trial is on track to be completed by the end of 2024.
TNDM’s Sigi, ergonomic, rechargeable and detachable patch pumps are under development. Additionally, it is driving innovation in algorithms. The company is planning to roll out its newest algorithm on both h t:slim X2 and Mobi.
TNDM Stock’s Key Headwinds
Tough Competitive Pressure: Tandem Diabetes operates in a highly competitive environment dominated by firms ranging from large multinational corporations (with significant resources) to start-ups. The company’s primary competitors are major publicly traded medical device companies, divisions, or subsidiaries of publicly traded companies, including Insulet and Medtronic. In addition, several companies have been developing and marketing their insulin delivery systems and related software applications. These significant changes within the industry may affect the company’s business and operating results.
Image Source: Zacks Investment Research
Macroeconomic Headwinds Persist: The uncertainties related to the current global economic and political conditions would pose challenges for the company. Due to unfavorable general economic conditions, Tandem Diabetes’ profitability could decline and affect its overall financial performance. In the third quarter, the cost of sales increased 24.5% from the prior-year level.
Estimate Trend
The Zacks Consensus Estimate for 2024 loss per share has moved down 4.5% to $1.68 in the past 30 days.
The Zacks Consensus Estimate for 2024 revenues is pegged at $912.5 million, which suggests an increase of 22% from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Globus Medical (GMED - Free Report) and Penumbra (PEN - Free Report) .
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.
HAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical, carrying a Zacks Rank #2 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.
Penumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.